How to Make Accumulator, Maximizer Programs More Acceptable to Your Patients l AMCP Nexus 2022
Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways...
Subscriber login:
SUBMIT
Remember me
Search
- Aug 22
High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023
The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already...
- Jul 20
California Initiative Provides $100 Million to Produce Its Own Insulin Biosimilars
The budget allocates half of the money for the development of low-cost interchangeable insulin biosimilars and the other half for...
- Jul 15
Biogen/ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
ICER's expert group unanimously voted against Biogen's Aduhelm and its benefit for Alzheimer's patients. (Biogen) By Noah Higgins-Dunn |...
- Jun 21
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...
- May 31
6 Payor Tactics to Control Drug Spending
By Karen Blum | specialtypharmacycontinuum.com The growth of high-cost specialty drugs is causing payors to scramble to manage spending...
- May 31
Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...
- May 29
New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says
With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...
- May 25
Payer Management Tools and Trends for Biosimilars in the US
As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...
- Apr 11
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...
- Mar 31
Upcoming Generics Provide New Considerations and Opportunities for Savings
In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...
- Mar 29
Jeffery Casberg Previews His Presentations at AMCP 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products...
- Mar 25
Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022
The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty...
- Nov 18, 2021
How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options
An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.
- Nov 1, 2021
IPD Executive Offers Perspective on Biosimilar Uptake and Policy
Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.
- Nov 1, 2021
Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve
Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.
- Oct 27, 2021
An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
Competitors in the field of adalimumab and insulin products may soon include authorized biologics.
- Oct 22, 2021
AMCP Nexus 2021: A Wrap-Up
Biosimilar adoption and biosimilar market share were among the featured topics at the AMCP Nexus 2021 meeting in Denver, Colorado.
- Oct 21, 2021
AMCP Nexus 2021: Biosimilars Are Gathering Momentum — and Interchangeability May Not Matter
IPD Analytics discussed biosimilar uptake as both biosimilar market share and adoption of biosimilars become more prominent.
- Apr 20, 2021
Further Dissecting the Launch of Adalimumab Biosimilars in the US
According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.